Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Another 20% down in 3 days,
What a POS.
10 years of investing in HALO did.nt deliver 1 cent.
Bad investment, My own fault.
Percy
Even my investment @8.35 is in danger.
Why did.nt I sell @25.00
Fool
Percy
Chapter 11 for HALO?
Percy
WTF, down 50% in 4 weeks??????
Any reason?
Percy
Barclays Initiates Coverage on Halozyme Therapeutics at Overweight, Announces $27.00 PT
Read more: http://www.benzinga.com/news/15/09/5855077/barclays-initiates-coverage-on-halozyme-therapeutics-at-overweight-announces-27-0#ixzz3mTLtnvAo
Percy
What's happening?
I almost doubled my last buy of 8,35.
MBO?
Perccy
No movement on the shortsellers-front
I wonder how they did when it went from 8$ to 15$
Settlement Date
Short Interest
Avg Daily Share Volume
Days To Cover
2/13/2015 20,296,260 1,315,867 15.424249
1/30/2015 20,837,822 1,661,712 12.539972
1/15/2015 21,397,311 4,327,942 4.943992
12/31/2014 19,718,416 1,625,899 12.127700
12/15/2014 20,079,879 965,595 20.795343
11/28/2014 20,457,384 742,600 27.548322
Read more: http://www.nasdaq.com/symbol/halo/short-interest#ixzz3SrrLazcl
in what way?
I'm not an expert on medical issues
Percy
Does this infect HALO, Fritz?
Percy
Short interest
are they covering now?
Settlement Date
Short Interest
Avg Daily Share Volume
Days To Cover
1/15/2015 21,397,311 4,327,942 4.943992
12/31/2014 19,718,416 1,625,899 12.127700
12/15/2014 20,079,879 965,595 20.795343
11/28/2014 20,457,384 742,600 27.548322
11/14/2014 21,137,564 1,231,491 17.164205
10/31/2014 20,908,590 1,131,288 18.482111
Read more: http://www.nasdaq.com/symbol/halo/short-interest#ixzz3QJhZsJqu
?
Looks like somebody is short here.
Percy
Won't complain about it now.
LOL
Congrats all you fellow-believers.
The future looks bright .
GLTUA
Percy
S H O R T S Q U E E Z E.
Back to the old level of 18 or even much more
Percy
Unusual option activity.
http://www.benzinga.com/trading-ideas/long-ideas/15/01/5123119/what-investors-are-looking-for-after-seeing-unusual-options-a
Some recent news has Halozyme Therapeutics, Inc.
HALO 0.7%
trending back in the right direction after a rocky 2014.
On December 17, Janssen entered into a partnership agreement to commercialize subcutaneous products using ENHAZE technology. Halozyme is also partnered with Pfizer Inc.
PFE 0.83%
, Baxter International Inc.
BAX 0.53%
and Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY).
Halozyme has several upcoming catalysts in the next few weeks, and options activity has spiked ahead of these events.
On Friday, the January 17 $10 Calls printed an 800 contract buy off the ask and 1,300 total volume on the day. On Monday, the January 17 $11 Calls printed a 2,000 contract buy off the ask near the close of the day.
Final volume on the day was 2,547, versus an open interest of only 222. The January 17 $10 calls also traded 534 more contracts on the day.
The following events could bring some volatility into the stock.
Halozyme announced that on January 7, at 10 a.m. EST, it will hold an investor conference to discuss the following: the science of PEGPH20, an update on the pancreatic cancer program, plans to evaluate PEGPH20 in Non-Small Cell Lung Cancer, and the evaluation of PEGPH20 in combination with other Immuno-oncology agents.
The company will also be presenting at the J.P. Morgan Healthcare Conference on January 13, at 7 p.m EST.
Additionally, the company will be at the ASCO GI conference between January 16 and 18. At the conference, the company will present the final progression free survival and overall survival data for its Phase 1B Study 201 trial.
That data should be lifted from embargo on January 12.
Disclosure: the author is long HALO
Read more: http://www.benzinga.com/trading-ideas/long-ideas/15/01/5123119/what-investors-are-looking-for-after-seeing-unusual-options-a#ixzz3O4uJpdZJ
Percy
Bosulif and sprycel are for CML (My wife has that).
Have been using Bosulif for a while. Works good for the leukemia, but has a lot of sideaffects.
Sutent is for pancreascancer, in that field she can be useful.
Percy
Again some covering.
Settlement Date
Short Interest
Avg Daily Share Volume
Days To Cover
12/15/2014 20,079,879 965,595 20.795343
11/28/2014 20,457,384 742,600 27.548322
11/14/2014 21,137,564 1,231,491 17.164205
10/31/2014 20,908,590 1,131,288 18.482111
10/15/2014 20,712,893 1,390,699 14.893872
9/30/2014 19,874,337 1,426,863 13.928693
Read more: http://www.nasdaq.com/symbol/halo/short-interest#ixzz3N0HDgTCX
MLV & Co. initiated coverage on Halozyme Therapeutics (NASDAQ: HALO) with a Buy rating and a price target of $12.00.
For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.
Percy
Nice Fritz.
Time for another SQEEZE>
Percy
Not so long ago we hit $18,-
Now we are in better shape than ever, but due to shortsellers we barely @ $8
Percy
Great news.
Hope shorts will back up once and for all.
But I'm afraid they wont.
Percy
Halozyme Announces Presentations Of Preclinical Data At The San Antonio Breast Cancer Symposium Annual Meeting
.
PR Newswire
Halozyme Therapeutics, Inc.
5 minutes ago
SAN DIEGO, Dec. 12, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO) announced that two scientific poster presentations on the pharmacology of PEGPH20 will be made at the 37th Annual San Antonio Breast Cancer Symposium (SABCS) today. The first of the presentations includes preclinical data showing that treatment of tumors with PEGPH20 enhances the action of immune-based cancer therapy such as monoclonal antibodies (mAbs). The second presentation includes additional supportive preclinical information on the utility of hyaluronan (HA) as a potential biomarker for cancer treatments. PEGPH20 is an investigational PEGylated form of rHuPH20 under development by Halozyme. PEGPH20 degrades the hyaluronan coating that may provide a supportive environment in many solid tumors.
SABCS Poster Presentation Details
Title: "Hyaluronan Depletion Sensitizes HAhigh Tumors to Antibody-Dependent Cell-Mediated Cytotoxicity"
Poster Session: P5-04-02, December 12, 2014, 7:00AM - 7:00PM CDT
Location: Exhibit Hall A-B
Summary: About 50% of HER2+3 breast cancers and 12% of ovarian cancers accumulate abundant HA in the tumor microenvironment. The accumulation of HA is known to result in decreased access of therapeutics to the tumor. Therefore, HA accumulation may contribute to trastuzumab resistance. When HA is depleted by treatment with PEGPH20 in vitro, HAhigh/HER2+3 cells become much more sensitive to antibody-mediated cellular cytotoxicity. Additionally, HAhigh/HER2+3 human tumors in mice treated with PEGPH20 increased the access of trastuzumab and immune cells to the tumor, resulting in enhanced antitumor activity. These results suggest that co-administration of PEGPH20 could enhance the efficacy of trastuzumab in HAhigh/HER2+3 tumors.
Title: "Naked Mole Rat HAS2 and Hyaluronan Are Not Tumor Suppressive in Human Tumor Xenografts"
Poster Session: P4-04-25, December 12, 2014, 7:00AM - 7:00PM CDT
Location: Exhibit Hall A-B
Summary: Published third-party literature suggests that naked mole rat hyaluronan synthase 2 (nmrHAS2) produces extraordinarily high molecular weight HA, which has tumor suppressive effects. Transfection of the nmrHAS2 gene into human tumor cells did not suppress the growth of human tumors in nude mice and suggests that HA in the naked mole rat may have different functions than in human cancer, where HA accumulation promotes tumor growth.
Short Interest.
Finally some covering.
Settlement Date
Short Interest
Avg Daily Share Volume
Days To Cover
11/28/2014 20,457,384 742,600 27.548322
11/14/2014 21,137,564 1,231,491 17.164205
10/31/2014 20,908,590 1,131,288 18.482111
10/15/2014 20,712,893 1,390,699 14.893872
9/30/2014 19,874,337 1,426,863 13.928693
9/15/2014 18,552,207 1,443,107 12.855739
Will HALO be next?
Japan’s Otsuka to buy U.S. drug maker Avanir for $3.5 billion
Short interest
Settlement Date
Short Interest
Avg Daily Share Volume
Days To Cover
11/14/2014 21,137,564 1,231,491 17.164205
10/31/2014 20,908,590 1,131,288 18.482111
10/15/2014 20,712,893 1,390,699 14.893872
9/30/2014 19,874,337 1,426,863 13.928693
9/15/2014 18,552,207 1,443,107 12.855739
8/29/2014 17,898,113 795,252 22.506216
8/15/2014 17,989,585 1,329,986 13.526146
Read more: http://www.nasdaq.com/symbol/halo/short-interest#ixzz3KC4YA9JK
55% premium for prosensa
http://investors.bmrn.com/releasedetail.cfm?ReleaseID=884456
Percy
My last buy @8.35 was'nt so brilliant.
Percy
Short interest still way too high.
Settlement Date
Short Interest
Avg Daily Share Volume
Days To Cover
10/31/2014 20,908,590 1,131,288 18.482111
10/15/2014 20,712,893 1,390,699 14.893872
9/30/2014 19,874,337 1,426,863 13.928693
9/15/2014 18,552,207 1,443,107 12.855739
8/29/2014 17,898,113 795,252 22.506216
8/15/2014 17,989,585 1,329,986 13.526146
Read more: http://www.nasdaq.com/symbol/halo/short-interest#ixzz3IrlXtoiR
Just hoping we are not getting any downgrades.
Percy
Bought some more at 8.35.
Helenss story convinced me. Big deals coming up
GLTU
Percy
Why down after hours?
Percy
Why is it down 8%n
Short Interest.
Settlement Date
Short Interest
Avg Daily Share Volume
Days To Cover
10/15/2014 20,712,893 1,390,699 14.893872
9/30/2014 19,874,337 1,426,863 13.928693
9/15/2014 18,552,207 1,443,107 12.855739
8/29/2014 17,898,113 795,252 22.506216
8/15/2014 17,989,585 1,329,986 13.526146
7/31/2014 17,672,741 1,468,885 12.031399
fotd sorry to offend you,
I am just an old frustraded investor, who does not like to be manipulated.
You are right to buy more, I should do that too.
HALO's fundamentals are great.
GLTU
Percy
some fools bought at 8.80 today
Dont they know that this stock is the most heavily shorted share on the nasdaq.
Percy
testing 8.00 today.
Percy
This does not suprise me...
Date
Short Interest
Avg Daily Share Volume
Days To Cover
9/30/2014 19,874,337 1,426,863 13.928693
9/15/2014 18,552,207 1,443,107 12.855739
8/29/2014 17,898,113 795,252 22.506216
8/15/2014 17,989,585 1,329,986 13.526146
7/31/2014 17,672,741 1,468,885 12.031399
7/15/2014 16,783,559 1,253,142 13.393182